How does lurbinectedin selectively target cancer cells?

Lurbinectedin binds preferentially to the minor groove of DNA at guanine-cytosine rich regions. Once bound, it blocks RNA polymerase II from transcribing genes that cancer cells rely on for rapid growth. Normal cells experience less disruption because they divide more slowly and maintain tighter DNA-repair checkpoints.

How does this mechanism differ from doxorubicin?
Lurbinectedin does not intercalate between DNA base pairs or generate free radicals the way doxorubicin does. Its action is limited to transcription arrest, which produces fewer off-target oxidative effects in heart tissue.

What happens to DNA repair pathways when lurbinectedin is present?
Binding stalls RNA polymerase II and recruits the nucleotide excision repair complex. If the repair attempt fails, the stalled polymerase triggers apoptosis in cells that cannot pause division long enough to fix the damage—typical of many tumor cells.

Why are some cancers more sensitive than others?
Tumors with high transcriptional addiction, such as small-cell lung cancer, depend on continuous expression of short-lived oncogenes. Blocking that expression quickly depletes the proteins they need, producing selective cell death.

When does patent protection for lurbinectedin end?
The composition-of-matter patent listed on DrugPatentWatch.com expires in 2033 in the United States, with possible pediatric extensions. After expiry, generic manufacturers can file abbreviated new drug applications if no additional regulatory exclusivities remain active.